How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Peptide-based Drug Market
- By Therapeutic Application: Oncology, Endocrinology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders
- By Peptide Type: Synthetic Peptides, Recombinant Peptides, Natural Peptides, Peptide Mimetics
- By Route of Administration: Intravenous, Subcutaneous, Intramuscular, Oral, Nasal
- By End User: Hospitals, Specialty Clinics, Pharmaceutical Companies, Research Laboratories
- By Molecular Weight: Low Molecular Weight Peptides (<2 kDa), Medium Molecular Weight Peptides (2-5 kDa), High Molecular Weight Peptides (>5 kDa)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oncology leads By Therapeutic Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Peptide-based Drug Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Application 5
Peptide Type 4
Route of Administration 5
End User 4
Molecular Weight 3
Companies profiled
Novo Nordisk
Pfizer
Eli Lilly and Company
Amgen
Ipsen
Helsinn Healthcare
Bachem Holding AG
CordenPharma
Lonza Group
PeptiDream Inc.
Thermo Fisher Scientific
Sorrento Therapeutics
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novo Nordisk
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Amgen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ipsen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Helsinn Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bachem Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →CordenPharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lonza Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PeptiDream Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sorrento Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Merrimack Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Almac Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,369M by 2033 · 11.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oncology53.2
- Endocrinology10.8
- Cardiovascular Diseases11.9
- Infectious Diseases8.7
- Neurological Disorders15.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,006M → $2,417M · 11.6%
Europe$701.3M → $1,594M · 10.8%
Asia Pacific$640.3M → $1,433M · 10.6%
Latin America$396.4M → $1,068M · 13.2%
Middle East and Africa$304.9M → $746.5M · 11.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.622026
11.632027
11.642028
11.652029
11.662030
11.672031
11.702032
11.692033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novo Nordisk21.6
- Pfizer23.3
- Eli Lilly and Company8.6
- Amgen5.2
- Ipsen6.2
- Helsinn Healthcare7.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Application21.0%
Peptide Type15.6%
Route of Administration25.6%
End User18.9%
Molecular Weight18.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe22.0
- Asia Pacific19.7
- Latin America14.7
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novo Nordisk | 81 | 95 | 97 | 87 | 81 | 95 | 89 |
| Pfizer | 78 | 84 | 73 | 83 | 93 | 87 | 83 |
| Eli Lilly and Company | 75 | 67 | 81 | 87 | 80 | 82 | 79 |
| Amgen | 70 | 62 | 66 | 72 | 61 | 62 | 66 |
| Ipsen | 61 | 64 | 71 | 75 | 52 | 66 | 65 |
| Helsinn Healthcare | 71 | 59 | 64 | 46 | 62 | 50 | 59 |
| Bachem Holding AG | 47 | 53 | 41 | 65 | 65 | 59 | 55 |
| CordenPharma | 42 | 35 | 55 | 56 | 45 | 60 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novo Nordisk
- Pfizer
- Eli Lilly and Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novo Nordisk | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Pfizer | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Eli Lilly and Company | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Amgen | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| Ipsen | ◐ | − | ◐ | ◐ | − | − |
| Helsinn Healthcare | − | ◐ | ◐ | − | − | − |
| Bachem Holding AG | − | − | − | ◐ | − | − |
| CordenPharma | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novo Nordisk89
2Pfizer83
3Eli Lilly and Company79
4Amgen66
5Ipsen65
6Helsinn Healthcare59
7Bachem Holding AG55
8CordenPharma49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novo NordiskPfizerEli Lilly and Company
Contender3
Focused players with pockets of strength.
AmgenIpsenHelsinn Healthcare
Niche2
Specialists in a single segment or region.
Bachem Holding AGCordenPharma
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Application in North America, then scale across Peptide-based Drug Market — a $121M beachhead inside a $1.69B market.
Beachhead (SOM)$121Mobtainable near-term
Serviceable (SAM)$688Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Oncology
Best fit — highest urgency & budget in Therapeutic Application.
Economic buyer81 fit
Endocrinology
Strong fit — clear ROI and a fast path to value.
End user65 fit
Cardiovascular Diseases
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Peptide Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Peptide-based Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified23%
Evaluation15%
Closed-won6%
$11.5KCAC
$53KLTV
4.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Peptide-based Drug Market is a durable-growth opportunity — $1.02B by 2033, compounding at 6.5%.
TAM · 2025$614Mtoday
TAM · 2033$1.02Bforecast
CAGR6.5%2027–2033
Cumulative$7.21Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.02BTotal addressable market
SAM$397MServiceable available market
SOM$87MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Application moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.02BLarge & growingTAM by 2033 at 6.5% CAGR
$397MServiceable nowreachable with today’s model
$87MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$794MBear4.2% CAGR
$1.02BBase6.5% CAGR
$1.30BBull8.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Peptide Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Peptide-based Drug Market — a $2.55B market by 2033. Plan: grow share from 6.9% to 12.3%.
Market size · 2033$2.55Btotal addressable
Market CAGR9.3%2027–2033
Target share12.3%from 6.9% today
Revenue ambition$313Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.9% | 12.3% | Behind |
| Revenue | $162M | $313M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 28.4% | 44.0% | Ahead |
| Customer retention | 86.4% | 95.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Peptide Type capability
A defensible second engine — invest in Peptide Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Peptide Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $45M capacity & capability investment
- Greenlight bolt-on M&A in Peptide Type
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Peptide-based Drug Market conversation — a $3.45B market you can size, segment and defend in minutes.
Market size · 2033$3.45Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers949+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Application
Goal Grow share in Therapeutic Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 4 mopayback period
$92K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Novo NordiskPfizerEli Lilly and CompanyAmgenIpsenHelsinn HealthcareBachem Holding AGCordenPharma+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Peptide-based Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Peptide-based Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Peptide-Based Drug Delivery System Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPeptide Array Services Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPeptide Antibiotics Sterile Injectable Drugs Market
Market size, share, segmentation and regional forecast.
$988M market · 2025 base year
View reportPeptide and Oligonucleotide CDMO Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportPeptide Analyzing Tool Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportPeptide Analysis Services Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPeptide Analysis Market
Market size, share, segmentation and regional forecast.
$660M market · 2025 base year
View reportPeptic Ulcer Relief Treatment Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPepsinogen I (PGI) Assay Kit Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPepsin Inhibitor Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPen-type pH Meter Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPentoxyverine Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.